Revelation Biosciences Stock Today
| REVB Stock | USD 3.79 0.39 9.33% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Revelation Biosciences is trading at 3.79 as of the 25th of February 2025, a 9.33 percent decrease since the beginning of the trading day. The stock's open price was 4.18. Revelation Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Note, on August 6, 2019, Senator Pat Toomey of US Senate acquired $15k to $50k worth of Revelation Biosciences's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of November 2020 | Category Healthcare | Classification Health Care |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company was founded in 2020 and is based in San Diego, California. Revelation Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 522.28 K outstanding shares of which 63.43 K shares are at this time shorted by private and institutional investors with about 0.13 trading days to cover. More on Revelation Biosciences
Moving against Revelation Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Revelation Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsRevelation Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Revelation Biosciences' financial leverage. It provides some insight into what part of Revelation Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Revelation Biosciences (REVB) is traded on NASDAQ Exchange in USA. It is located in 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 and employs 9 people. Revelation Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.18 M. Revelation Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 522.28 K outstanding shares of which 63.43 K shares are at this time shorted by private and institutional investors with about 0.13 trading days to cover.
Revelation Biosciences currently holds about 3.48 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Check Revelation Biosciences Probability Of Bankruptcy
Ownership AllocationRoughly 88.1 pct. of Revelation Biosciences outstanding shares are held by general public with 0.1 % owned by insiders and only 11.8 (%) by third-party entities. On August 6, 2019, Senator Pat Toomey of US Senate acquired $15k to $50k worth of Revelation Biosciences's common stock.
Check Revelation Ownership Details
Revelation Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-12-31 | 49.8 K | |
| Hrt Financial Llc | 2024-09-30 | 0.0 | |
| Sabby Management Llc | 2024-09-30 | 42.2 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 29.1 K | |
| Tower Research Capital Llc | 2024-12-31 | 2.5 K | |
| Sbi Securities Co Ltd | 2024-12-31 | 301 | |
| Royal Bank Of Canada | 2024-12-31 | 100.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 6.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Pom Investment Strategies, Llc | 2024-12-31 | 0.0 | |
| Bank Of America Corp | 2024-12-31 | 0.0 |
Revelation Biosciences Historical Income Statement
Revelation Stock Against Markets
Revelation Biosciences Corporate Management
| James Rolke | CEO Director | Profile | |
| Carol Odle | Director Projects | Profile | |
| Chester III | Chief Officer | Profile | |
| Sandra Vedrick | Vice Relations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.